leadf
logo-loader
viewGenprex, Inc.

Genprex making strides to take cancer-fighting drug Oncoprex to FDA approval

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company's non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval.

The company recently went public, raising $6.4mln. Varner says the biopharma will use the funds to continue clinical trials and expand and/or accelerate development programs into additional drug combinations.

Quick facts: Genprex, Inc.

Price: 3.62 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $140.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read